Search hospitals > Ontario > TORONTO
Mount Sinai Hospital
Claim this profileTORONTO, Ontario M5G 1X5
Global Leader in Postpartum Hemorrhage
Global Leader in Crohn's Disease
Conducts research for Breast Cancer
Conducts research for Chronic Persistent Surgical Pain
Conducts research for Pain
439 reported clinical trials
43 medical researchers
Summary
Mount Sinai Hospital is a medical facility located in TORONTO, Ontario. This center is recognized for care of Postpartum Hemorrhage, Crohn's Disease, Breast Cancer, Chronic Persistent Surgical Pain, Pain and other specialties. Mount Sinai Hospital is involved with conducting 439 clinical trials across 457 conditions. There are 43 research doctors associated with this hospital, such as Mrinalini Balki, MD, Jose Carvalho, MD, Yehoshua Gleicher, MD, MSc, and Christian Pagnoux, MD, MS, MPH.Area of expertise
1Postpartum Hemorrhage
Global LeaderFactor V Leiden positive
Prothrombin gene variant positive
Protein C positive
2Crohn's Disease
Global LeaderTop PIs
Mrinalini Balki, MDMount Sinai Hospital1 year of reported clinical research
Studies Postpartum Hemorrhage
Studies Labor Pain
13 reported clinical trials
11 drugs studied
Jose Carvalho, MDMount Sinai Hospital6 years of reported clinical research
Studies Postpartum Hemorrhage
Studies Diabetes Insipidus
7 reported clinical trials
11 drugs studied
Yehoshua Gleicher, MD, MScMount Sinai Hospital3 years of reported clinical research
Studies Total Knee Replacement
Studies Knee Replacement Surgery
6 reported clinical trials
10 drugs studied
Christian Pagnoux, MD, MS, MPHMount Sinai Hospital4 years of reported clinical research
Studies Vasculitis
Studies Granulomatosis with Polyangiitis
5 reported clinical trials
6 drugs studied
Clinical Trials running at Mount Sinai Hospital
Postpartum Hemorrhage
Bronchopulmonary Dysplasia
Labor Pain
Crohn's Disease
Cancer
Mental Health
Premature Birth
Postoperative Pain
Atrial Fibrillation
Colorectal Cancer
Carbetocin vs Oxytocin
for Postpartum Hemorrhage
The goal of this study is to compare 2 medications that are commonly used to prevent excess uterine bleeding (postpartum hemorrhage, or PPH) following cesarean delivery (CD), oxytocin and carbetocin. Most of the trials evaluating the preventative role of oxytocin and carbetocin after CD have focused on patient with low-risk of PPH. This trial will focus on patients that are at increased risk of PPH, with risk factors such as: multiple gestation (twins, or more multiples), large baby, polyhydramnios (excess amniotic fluid), history of PPH, body mass index greater than 40, diabetes mellitus, hypertension, and placenta previa. The investigators hypothesize that carbetocin would be more effective than an oxytocin regimen in reducing the risk of PPH in patients undergoing CD with any of the biological high-risk factors.
Recruiting1 award N/A
Carbetocin
for Postpartum Hemorrhage
Postpartum hemorrhage (PPH) continues to be an increasing problem globally. Uterotonics play an essential role in the pharmacological management of uterine atony. Carbetocin, a long acting analog of oxytocin has been recommended as a first line uterotonic for PPH prophylaxis at cesarean delivery. Considering many woman have associated comorbidities and are at high risk of PPH, finding alternative pharmacological agents is essential. Calcium is a key factor for myometrial contractions and calcium blood levels can be low at the end of pregnancy. Both hypocalcemia and hypercalcemia could lead to a decrease in myometrial contractions. It is already been demonstrated that in both desensitized and naïve myometrium, normocalcemia provides a better uterine tone compared to hypo and hypercalcemia when oxytocin is given as the first uterotonic drug. Currently, the role of extracelullar calcium in carbetocin- induced contractility is unknown. This will be the first ex vivo study to test the effects of extracellular calcium on oxytocin pretreated and naive myometrium. The results of this study will provide evidence on the use of this safe drug in clinical practice, particularly in women with labour arrest, and provide alternative pharmacological strategies to both prevention and treatment of PPH, thus improving our clinical practice. The investigators hypothesize that extracellular normocalcemia would provide superior carbetocin-mediated contractility in both naive and oxytocin-pretreated myometrium compared with hypercalcemia and hypocalcemia.
Recruiting1 award N/A1 criteria
Oxytocin
for Postpartum Hemorrhage
This study is designed to determine the minimal effective oxytocin maintenance infusion required in labouring women undergoing cesarean delivery to achieve the best effect. Oxytocin is a drug that is routinely used to help the uterus to contract and keep it contracted after delivery. Consequently, it will help to reduce blood loss after delivery. In order to determine the minimal effective dose, the investigators will conduct a dose-finding study. The first patient will receive a set oxytocin infusion. The next patient's infusion dose of oxytocin, will either increase or decrease, depending on how the previous patient responds in terms of uterine tone. If the response is satisfactory with the infusion dose used, the next patient will either receive the same infusion dose or it will be decreased depending on a probability of 1:9. If the response is not satisfactory, then the infusion dose will increase for the next patient. The dose for each patient will be determined based on the results of the uterine contraction of the previous patient. The investigators hypothesize that the ED90 of the oxytocin infusion rate to maintain adequate uterine tone in labouring women with induced or augmented labour undergoing cesarean delivery, following an initial effective bolus dose, would be lower than 0.74 IU/min (44 IU/h), which was found as the ED90 in a previous study, without an initial bolus dose prior to the infusion.
Recruiting1 award N/A
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Mount Sinai Hospital?
Mount Sinai Hospital is a medical facility located in TORONTO, Ontario. This center is recognized for care of Postpartum Hemorrhage, Crohn's Disease, Breast Cancer, Chronic Persistent Surgical Pain, Pain and other specialties. Mount Sinai Hospital is involved with conducting 439 clinical trials across 457 conditions. There are 43 research doctors associated with this hospital, such as Mrinalini Balki, MD, Jose Carvalho, MD, Yehoshua Gleicher, MD, MSc, and Christian Pagnoux, MD, MS, MPH.
Where is Mount Sinai Hospital located?
Mount Sinai Hospital is located at 600 University Ave, Toronto, ON M5G 1X5. For subway access, take the Spadina-University line to Queen's Park Station or the College/Carlton streetcar to University Avenue. The hospital is situated south of College Street on the west side.
Who should I call to ask about financial aid or insurance network?
**Mount Sinai Medical Center Financial Assistance:**
- **Customer Service:** 305-674-2130
- **Availability:** Monday-Friday, 9:00am to 4:00pm
**The Mount Sinai Hospital Insurance and Billing Inquiries:**
- **Patient Financial Services:** 212-731-3100 or Toll-Free 866-682-9380
- **Availability:** Monday-Friday, 9:00am to 5:00pm
What insurance does Mount Sinai Hospital accept?
Mount Sinai Hospital accepts a wide range of insurance plans, including but not limited to Aetna HMO/PPO/POS/Medicare, Cigna HMO/PPO/EPO/POS, Empire BCBS PPO/POS/EPO/HMO, EmblemHealth, Fidelis, GHI, Healthfirst, HIP, Magnacare, Medicare, PHCS/Multiplan, Oscar, Oxford, POMCO, and United Healthcare. It's important to know that physician services provided in the hospital are billed separately from hospital charges. Patients should verify with their physician which insurance plans are accepted to ensure coverage.
What awards or recognition has Mount Sinai Hospital received?
Mount Sinai Hospital, located in Toronto, Ontario, is celebrated for its exceptional specialty programs, earning a spot in Newsweek's World's Best Specialized Hospitals 2023 for its groundbreaking diabetes research. It houses the Lunenfeld-Tanenbaum Research Institute, a leading biomedical research facility globally renowned for its comprehensive studies in women's and infants' health, cancer biology, stem cell biology, neurobiology, diabetes, arthritis, and more. This institution is dedicated to advancing health systems research, population health services, and systems biology.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.